Disease & disorder

multiple sclerosis

MONDO:0005301

A progressive autoimmune disorder affecting the central nervous system resulting in demyelination. Patients develop physical and cognitive impairments that correspond with the affected nerve fibers.

Clinical trials2,540
Recruiting264
Drug concepts studied20
Synonyms2

Research intelligence

Directly mapped studies only · unique clinical trials

Current registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.

Medications under investigation

Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.

Loading mapped interventions…

MONDO disease family

Loading verified ontology relationships…

Recruiting studies by city

Loading research-site locations…

Trial status

Loading…

Trial phase

Loading…

Study start year

Loading…

Investigated drug interventions

Loading…
Background context

Multiple sclerosis

Multiple sclerosis (MS) is a chronic and neurodegenerative autoimmune disease in which the immune system attacks myelin, the insulating cover of nerve cells, causing damage to the central nervous system. This impairs the nervous system's ability to transmit signals. Symptoms include double vision, vision loss, eye pain, muscle weakness, loss of coordination, as well as cognitive issues like problems with memory. MS may be a rare complication of an Epstein-Barr virus (EBV) infection. Genetics and environmental factors like exposure to sunlight also impact the risk of MS. MS can be diagnosed based on symptoms, MRI scans, and sometimes a lumbar puncture to investigate spinal fluid. There is no cure for MS. Current treatments aim to manage symptoms during acute flares and prevent further attacks with disease-modifying therapies. With effective treatment, it is possible to reduce attacks strongly, but the disease progress is not fully stopped. In addition, symptoms of MS like balance issues can be managed with drugs and with non-drug treatments (e.g. physical therapy). On average, life expectancy is slightly lower than normal. In 2024, about 3.1 million people were affected by MS globally, with rates much higher further from the equator. The disease usually begins between the ages of 20 and 40 and is almost three times more common in women than in men. MS was first described in 1868 by French neurologist Jean-Martin Charcot.

Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

40 shown
A Phase 1/2a Study of Oral PRO-1562 in Healthy Subjects and Patients With Relapsing Multiple SclerosisNCT07826689 · 2026-10-01
RECRUITING
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 TherapyNCT07609719 · 2026-09-02
RECRUITING
Short Sprint Interval Training in People With Multiple SclerosisNCT07804264 · 2026-09-01
RECRUITING
Delivery of a Culturally Tailored Exercise Training Intervention for Hispanics With Multiple SclerosisNCT07606742 · 2026-08-24
RECRUITING
Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility StudyNCT07759115 · 2026-08-10
RECRUITING
Understanding the Impact of Meal Timing on Neurological Health in Adults With Multiple SclerosisNCT07475377 · 2026-08-01
RECRUITING
Cooling During Inpatient Rehabilitation in Persons With MSNCT07852156 · 2026-07-28
RECRUITING
Single Arm Trial Identifying Barriers and Facilitators to Mindfulness PracticeNCT07573241 · 2026-07-17
RECRUITING
Ocrevus Zunovo for MS: Mixed MethodsNCT07710105 · 2026-06-12
RECRUITING
Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to ZeposiaNCT07732907 · 2026-06-04
RECRUITING
Hyperpolarized Carbon Metabolic Imaging in Multiple SclerosisNCT07510607 · 2026-06-03
RECRUITING
Fatigue Investigation Using Digital OutcomesNCT07783074 · 2026-05-26
RECRUITING
Auditory Functions in Patients With Multiple SclerosisNCT06164483 · 2026-05-11
RECRUITING
Dry Needling in Multiple SclerosisNCT07615725 · 2026-05-08
RECRUITING
Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple SclerosisNCT07587125 · 2026-05-08
RECRUITING
Monitoring Intensity During Balance Training in Persons With Multiple SclerosisNCT07805850 · 2026-05-06
RECRUITING
ATLG Levels in Autologous HSCT for Multiple SclerosisNCT07635693 · 2026-05-04
RECRUITING
Effects of Sleep Quality on Functional and Cognitive Outcomes in Multiple SclerosisNCT07536503 · 2026-05-01
RECRUITING
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple SclerosisNCT07497399 · 2026-04-28
RECRUITING
Caregiver Burden in Caregivers of Patients With Multiple SclerosisNCT07549048 · 2026-04-20
RECRUITING
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic DiseasesNCT07304154 · 2026-04-10
RECRUITING
A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world PracticeNCT07779460 · 2026-04-08
RECRUITING
A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)NCT07503873 · 2026-04-01
RECRUITING
Silodosin for Urinary Symptoms in Female Patients With Multiple SclerosisNCT07614321 · 2026-04-01
RECRUITING
MB-CART2019.1 in Refractory Multiple SclerosisNCT07178431 · 2026-04-01
RECRUITING
EXOPULSE Suit and Walking Ability of Patients With Multiple SclerosisNCT07252895 · 2026-03-30
RECRUITING
Relationship Between Single- and Dual-Task Obstacle Crossing Performance and Fatigue and Disability in Multiple SclerosisNCT07736482 · 2026-03-20
RECRUITING
How to Develop the Highest Possible Leading-edge Interdisciplinary Care Model for People With MS, That Will be Relevant to All Stakeholders and Declinable to Different Local Contexts With the Ultimate Goal of Ensuring the Highest Level of Quality of Care in MS.NCT07289724 · 2026-03-18
RECRUITING
Reliability and Validity of Three DT-TUG Protocols in MSNCT07788859 · 2026-03-16
RECRUITING
Investigating Specific Gait Patterns in Individuals Living With Multiple SclerosisNCT07388992 · 2026-03-16
RECRUITING
The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Walking, Balance, and Cognitive Functions in Individuals With Multiple SclerosisNCT07507084 · 2026-03-15
RECRUITING
Evaluation of the Effects of Laughter YogaNCT07524231 · 2026-03-10
RECRUITING
This is an Early Exploratory Study to Assess the Tolerability and Safety of GC012F in Patients With Multiple SclerosisNCT07303790 · 2026-03-09
RECRUITING
Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM ActivityNCT07236684 · 2026-03-09
RECRUITING
URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSISNCT07489794 · 2026-03-09
RECRUITING
Skeletal Muscle Aging and Responsiveness in Aged People With MSNCT07500727 · 2026-03-06
RECRUITING
VR and Orthoses for Rehabilitation in Multiple SclerosisNCT07096700 · 2026-03-02
RECRUITING
Non-invasive Brain Stimulation in Multiple Sclerosis FatigueNCT07438964 · 2026-03-02
RECRUITING
Treatment of Participants With Primary or Secondary Progressive Multiple SclerosisNCT07477639 · 2026-03-01
RECRUITING
Effectiveness of TMS on Spasticity and Balance for Patients With MSNCT07451600 · 2026-03-01
RECRUITING

Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.